Relationship Between Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Dose and Clinical Outcome Following Acute Myocardial Infarction

DOI Web Site Web Site PubMed 被引用文献1件 参考文献29件
  • Grall Sylvain
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Biere Loïc
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Le Nezet Marie
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Bouvier Jean-Marc
    Cardiology Department, Hospital of Cholet
  • Lucas-Chauvelon Pierre
    ardiology Department, Haut-Anjou Hospital
  • Richard Claude
    Cardiology Department, Hospital of Saumur
  • Abi-Khalil Wissam
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Delepine Stéphane
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Prunier Fabrice
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers
  • Furber Alain
    Laboratoire Cardioprotection, Remodelage et Thrombose, University of Angers, L’UNAM University and Cardiology Department, University Hospital of Angers

この論文をさがす

抄録

Background:Benefit of β-blockers (BB) and angiotensin-converting-enzyme inhibitors (ACEI) on mortality following acute myocardial infarction (MI) is well demonstrated. This study assessed the impact of BB and ACEI doses administered following ST-elevation MI on mortality and outcome up to 1 year.Methods and Results:The French prospective observational cohort “RIMA” included 1,461 MI patients. Dosing of BB and ACEI given at 24 h and at time of discharge was assessed as follows: no treatment; <50% of target dose; or ≥50% of target dose. For in-hospital mortality, after MI, the use of BB in the first 24 h, but not ACEI, was associated with significantly lower event rate on multivariate analysis (OR, 5.78; 95% CI: 2.62–12.76, P<0.001). In contrast at 1 year, use of higher doses of ACEI, but not BB, was associated with significantly lower CV mortality, readmission for heart failure and the composite of CV mortality and readmission for heart failure (HR, 2.65; 95% CI: 1.32–5.31, P=0.006 for absence of ACEI at discharge).Conclusions:Prescription of BB in the first 24 h was independently associated with a lower in-hospital mortality following MI. There appeared to be a significant dose effect on outcome with regard to <50% vs. ≥50% of target dose, which requires confirmation in further large-scale clinical studies. (Circ J 2015; 79: 632–640)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (3), 632-640, 2015

    一般社団法人 日本循環器学会

被引用文献 (1)*注記

もっと見る

参考文献 (29)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ